Evidence map›Paper›PMID 35546463›Full record

ArticleIndian journal of pharmacology

Tert-Butylhydroquinone alleviates insulin resistance and liver steatosis in diabetes.

Tian-Tian Zhu, Chao-Nan Zhu, Ning Huang, Xin Yu, Guang-Rui Wan, Shuang-Xi Wang, Ping Song, Jian Xu, Peng Li, Ya-Ling Yin

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Indian journal of pharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Tian-Tian ZhuDepartment of Clinical Pharmacy, College of Pharmacy, Xinxiang Medical University; Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention; Xinxiang Key, Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China.
Chao-Nan ZhuDepartment of Clinical Pharmacy, College of Pharmacy, Xinxiang Medical University; Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention; Xinxiang Key, Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development; Department of Pharmacy, Xinxiang Medical University First Affiliated Hospital, Xinxiang, China.
Ning HuangDepartment of Clinical Pharmacy, College of Pharmacy, Xinxiang Medical University; Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention; Xinxiang Key, Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China.
Xin YuDepartment of Clinical Pharmacy, College of Pharmacy, Xinxiang Medical University; Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention; Xinxiang Key, Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China.
Guang-Rui WanDepartment of Clinical Pharmacy, College of Pharmacy, Xinxiang Medical University; Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention; Xinxiang Key, Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China.
Shuang-Xi WangDepartment of Clinical Pharmacy, College of Pharmacy, Xinxiang Medical University; Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention; Xinxiang Key, Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China.
Ping SongDepartment of Clinical Pharmacy, College of Pharmacy, Xinxiang Medical University; Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention; Xinxiang Key, Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China.
Jian XuDepartment of Clinical Pharmacy, College of Pharmacy, Xinxiang Medical University; Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention; Xinxiang Key, Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China.
Peng LiDepartment of Clinical Pharmacy, College of Pharmacy, Xinxiang Medical University; Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention; Xinxiang Key, Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China.
Ya-Ling YinHenan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention; Xinxiang Key, Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xinxiang, China.
Xinxiang Medical University · CNXinxiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThis work aimed to determine tert-Butylhydroquinone (TBHQ)'s effects on insulin resistance (IR) and liver steatosis in diabetic animals and to explore the underpinning mechanisms. MATERIALS AND

methodsMale ApoE

resultsThe model animals showed T2DM signs, and TBHQ decreased FBG, ameliorated glucose tolerance and reduced liver steatosis in these animals. In addition, TBHQ markedly upregulated AMPKα2, GLUT4 and GSK3 β, as well as phosphorylated PI3K and AKT in the liver of mice with T2DM. In agreement, TBHQ decreased HClO-and insulin-related IR in cells and suppressed apoptosis through AMPKα2/PI3K/AKT signaling.

conclusionsTBHQ alleviates IR and liver steatosis in a mouse model of T2DM likely through AMPKα2/PI3K/AKT signaling.

Indexed as

Diabetes Mellitus, ExperimentalDiabetes Mellitus, Type 2Fatty LiverInsulin ResistanceAnimalsBlood GlucoseGlycogen Synthase Kinase 3HydroquinonesInsulinLiverMaleMicePhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-akt2-tert-butylhydroquinoneBlood GlucoseGlycogen Synthase Kinase 3HydroquinonesInsulinPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktAMPKα2insulin resistanceliver steatosistert-Butylhydroquinonetype 2 diabetes mellitus

Identifiers

PMID35546463
PMCPMC9249147
OpenAlexW4280515048

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.